BIONDVAX PHARMACEUTICALS-ADR (BVXV) Fundamental Analysis & Valuation

NASDAQ:BVXV • US09073Q2049

Current stock price

1.36 USD
+0.05 (+3.82%)
At close:
1.38 USD
+0.02 (+1.47%)
After Hours:

This BVXV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BVXV Profitability Analysis

1.1 Basic Checks

  • BVXV had negative earnings in the past year.
BVXV Yearly Net Income VS EBIT VS OCF VS FCFBVXV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • BVXV has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BVXV Yearly ROA, ROE, ROICBVXV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

  • BVXV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BVXV Yearly Profit, Operating, Gross MarginsBVXV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BVXV Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for BVXV has been increased compared to 1 year ago.
  • BVXV has a worse debt/assets ratio than last year.
BVXV Yearly Shares OutstandingBVXV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
BVXV Yearly Total Debt VS Total AssetsBVXV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • BVXV has an Altman-Z score of -7.98. This is a bad value and indicates that BVXV is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of BVXV (-7.98) is worse than 72.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.98
ROIC/WACCN/A
WACCN/A
BVXV Yearly LT Debt VS Equity VS FCFBVXV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 4.28 indicates that BVXV has no problem at all paying its short term obligations.
  • BVXV has a Current ratio (4.28) which is in line with its industry peers.
  • A Quick Ratio of 4.28 indicates that BVXV has no problem at all paying its short term obligations.
  • The Quick ratio of BVXV (4.28) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.28
Quick Ratio 4.28
BVXV Yearly Current Assets VS Current LiabilitesBVXV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BVXV Growth Analysis

3.1 Past

  • The earnings per share for BVXV have decreased strongly by -93.48% in the last year.
EPS 1Y (TTM)-93.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BVXV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.98% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.29%
EPS Next 2Y18.02%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BVXV Yearly EPS VS EstimatesBVXV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. BVXV Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BVXV. In the last year negative earnings were reported.
  • Also next year BVXV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BVXV Price Earnings VS Forward Price EarningsBVXV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BVXV Per share dataBVXV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BVXV's earnings are expected to grow with 24.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y24.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BVXV Dividend Analysis

5.1 Amount

  • BVXV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BVXV Fundamentals: All Metrics, Ratios and Statistics

BIONDVAX PHARMACEUTICALS-ADR

NASDAQ:BVXV (9/6/2023, 8:00:01 PM)

After market: 1.38 +0.02 (+1.47%)

1.36

+0.05 (+3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11
Earnings (Next)N/A
Inst Owners6.93%
Inst Owner Change0%
Ins Owners18.86%
Ins Owner Change0%
Market Cap4.97M
Revenue(TTM)N/A
Net Income(TTM)-10.92M
Analysts82.86
Price Target39.78 (2825%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.39%
Min EPS beat(2)-46.39%
Max EPS beat(2)-46.39%
EPS beat(4)2
Avg EPS beat(4)48.25%
Min EPS beat(4)-46.39%
Max EPS beat(4)109.8%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.86
EYN/A
EPS(NY)-2.6
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-1.32
TBVpS-1.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.28
Quick Ratio 4.28
Altman-Z -7.98
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)239.78%
Cap/Depr(5y)2174.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.5%
EPS Next Y99.29%
EPS Next 2Y18.02%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-229.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y91.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.08%
OCF growth 3YN/A
OCF growth 5YN/A

BIONDVAX PHARMACEUTICALS-ADR / BVXV Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BVXV.


What is the valuation status for BVXV stock?

ChartMill assigns a valuation rating of 1 / 10 to BIONDVAX PHARMACEUTICALS-ADR (BVXV). This can be considered as Overvalued.


How profitable is BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

BIONDVAX PHARMACEUTICALS-ADR (BVXV) has a profitability rating of 0 / 10.


What is the financial health of BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

The financial health rating of BIONDVAX PHARMACEUTICALS-ADR (BVXV) is 2 / 10.